FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18 Read more about FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting Read more about New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
bluebird bio Sells Priority Review Voucher for $102 Million Read more about bluebird bio Sells Priority Review Voucher for $102 Million
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
31st Annual Credit Suisse Healthcare Conference Read more about 31st Annual Credit Suisse Healthcare Conference
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference Read more about bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) Read more about bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall Read more about Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
bluebird bio Announces September Investor Events Read more about bluebird bio Announces September Investor Events